Molecular Diagnostics 2012

Technologies for molecular diagnostics are delivering new tools to the clinical community for faster and more accurate decision making.  Learning what the demands of the community are, where the unmet medical need is, and how the assays can best perform, are critical questions to be asking.  This meeting is the key conference for molecular diagnostics showcasing technologies and criteria for success such as market access and payment.  It will encompass payers and reimbursement, emerging markets, comparative effectiveness, and benefits to clinical trial management and therapy selection for patients.  In its ninth year, this meeting will present the dynamic factors shaping the industry, and the enormous growth opportunities that exist.

Who Should Attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as Diagnostics, Business Development, R&D, Chemistry, Clinical Research, in vitro Diagnostics, Personalized Healthcare, Process Development, and Oncology.

Topics will include, but are not limited to:

-Analytical validation of ultra HT sequencing
-Sample type and preparation for IVD test design
-Genomic data interpretation
-Genomic design of clinical decision support
-Commercialization of new tests
-Changing environment of regulation of LDTS
-Patient genotyping at clinical trial sites
-Challenges and practical applications of NGS in oncology